IgA Nephropathy Market to Exhibit Rapid Growth Rate | Chinook Therapeutics, RemeGen, Novartis, Ionis Pharma, Vera Therapeutics, Eledon Pharma, Guangdong Hengrui Pharma, companies are expected to change the IgA Nephropathy Market scenario by 2032, forecas

{Delhi, India} To strategically aid IgA Nephropathy companies developing drugs for IgA Nephropathy, DelveInsight launched a report titled as “IgA Nephropathy Market Insight, Epidemiology And Market Forecast - 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of IgA Nephropathy market.

Get a free sample of ”IgA Nephropathy Market Report”: 

Key Highlights from IgA Nephropathy market Report:

• Around USD 500 million was spent on IgA nephropathy in the 7MM and China in 2022, and this amount is expected to rise throughout the forecast period (2023–2032).
• With a market value of over USD 160 million in 2022, the IgA Nephropathy market size was the largest of the seven million in the US, and it is expected to continue growing through 2032.
• TARPEYO is merely a reformulated corticosteroid, and there is a great unmet need for targeted therapy for individuals with widespread disease, even though the initial medication was licensed and introduced for IgAN. A few promising medications are in development to address the need for innovative MoA in disease-specific targeted therapeutics. These therapies include Atrasentan (Chinook Therapeutics, Inc.), Iptacopan (Novartis Pharmaceuticals), and VIS649 (Visterra, Inc.). Narsoplimab is being developed by Omeros. 

IgA Nephropathy Country based Treatment Overview : 

An autoimmune condition known as IgA Nephropathy (IgAN) targets the kidneys. It has an impact on the kidneys' tiny blood vessels' ability to filter blood. IgAN develops when the kidneys' glomerulus, or filtering unit, is harmed by an aberrant protein.

Up till now, a kidney biopsy must demonstrate IgA to be the dominant or co-dominant immunoglobulin in the glomerular mesangium in order to diagnose IgAN. The pathophysiology of IgAN is yet unknown, though. While renal biopsy is still the preferred method for diagnosing IgAN, recent research has looked for novel biomarkers that can identify IgAN without a biopsy.

 Download the report to understand which factors are driving IgA Nephropathy epidemiology trends @ IgA Nephropathy Epidemiology Forecast

IgA Nephropathy Epidemiology Insights: 

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for IgA Nephropathy. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patients pools. The epidemiology in report is segmented as : 

IgA Nephropathy Epidemiology Segmentation:

• Total Prevalence of IgA Nephropathy
• Prevalent Cases of Heparin-inducedThrombocytopenia by severity
• Gender-specific Prevalence of IgA Nephropathy
• Diagnosed Cases of Episodic and Chronic IgA Nephropathy

“As per DelveInsight, IgA Nephropathy reported prevalent cases in the 7MM and China were ~1,899,000 cases in 2022 and are projected to increase during the forecast period (2023–2032). The total number of IgA Nephropathy prevalent cases in the United States was around ~193,700 cases in 2022.

In comparison to females, males have higher levels of IgAN. In Japan, there were roughly 51,000 females and 69,000 males with IgAN in 2021.

Japan accounted for about 88,000 diagnosed prevalent cases of IgA Nephropathy in 2022 

To know more about IgA Nephropathy companies working in the treatment market, visit @ IgA Nephropathy Clinical Trials and Therapeutic Assessment

IgA Nephropathy Market Insights:

• In February 2023, Travere Therapeutics’ dual endothelin angiotensin receptor antagonist FILSPARI, became the first non-immunosuppressive FDA-approved treatment for IgA Nephropathy, although still being put on REMS due to its potential hepatotoxic and embryo-fetal toxic effects.
• Additional novel treatments such as iptacopan from Novartis, narsoplimab from Omeros Corporation, atrasentan and BION-1301 from Chinook Therapeutics, atacicept from Vera Therapeutics, sibeprenlimab from Visterra, and telitacicept from Remegen are anticipated to make a substantial impact on the expanding market for IgA Nephropathy. 

IgA Nephropathy Market Forecast :

• Up until recently, immunosuppressants and ACEi/ARBs dominated the present therapy landscape. With a urine protein-to-creatinine ratio (UPCR) of typically ≥1.5g/g, individuals with IgAN who are at risk of rapid disease progression were given approval by the US FDA in December 2021 for the use of TARPEYO (budesonide) delayed release capsules. For people with primary IgA nephropathy (IgAN), this is the first and only recommended treatment for reducing proteinuria.
• "More should be done to identify IgAN in people with modest proteinuria and/or chronic microhematuria, and to loosen the guidelines for when kidney biopsies are appropriate. The worldwide burden of end-stage renal disease brought on by IgAN may be decreased by using this preventive strategy and early therapy.
• Robust pipeline of emerging IgA Nephropathy therapies, and Scientific advances and identification of novel biomarkers for disease diagnosis and monitoring of disease progression

 Discover more about therapies set to grab major IgA Nephropathy market share @ IgA Nephropathy Treatment Market

Scope of the IgA Nephropathy Market Report:

• Geography Coverage: 7MM
• Study Period: 2019-2032
• IgA Nephropathy Market Size: ~190 million in 2021
• Key IgA Nephropathy Companies: Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, and others.

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the IgA Nephropathy market landscape.

• Gain Competitive Edge in Indication Market: Understand the current landscape of the IgA Nephropathy market, including the competitive environment, key companies developing drugs for IgA Nephropathy , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the IgA Nephropathy market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing  with  IgA Nephropathy. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success: Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the IgA Nephropathy market with clarity and purpose.

Gain Competitive Edge in Indication Market: 

• Identify Market Gaps and indication market opportunities
• Strategic decision making
• Plan RoadMap to Success

Do you want to know how we helped our client Navigating the Asia-Pacific Life Sciences Landscape through Strategic Competitive Benchmarking : Download case study today!

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.



Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Gaurav Bora

Email: info@delveinsight.com

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com/consulting